HLN · NYSE
Haleon plc
$10.27 -0.11 (-1.06%)
Company overview
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands includes Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, Parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Exchange
- NYSE
- Market cap
- $45.3B
- Employees
- 24,561
- Headquarters
- Weybridge
- Website
- haleon.com
- CEO
- Brian James McNamara
- Listed
- July 25, 2022
- P/E
- 16.59
- Dividend yield
- 2.04%
Company financials
- Revenue
- $19.3B
- Gross profit
- $12.3B
- Operating income
- $4.1B
- EBITDA
- $4.8B
- Net income
- $2.8B
- EPS
- $0.62
- Total assets
- $32.6B
- Total debt
- $8.6B
- Gross margin
- 63.76%
- Net margin
- 14.43%
- Earnings yield
- 6.03%
No annual geographic segmentation.
Showing FY 2025
HLN
1D
NYSE
O10.13H10.40L10.12C10.37+0.35 (+3.49%)Vol14.62M